导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 1.37% | 1892/4773 |
| 近一周 | -1.50% | 481/5462 |
| 近一月 | 0.56% | 551/5421 |
| 近一季 | -2.84% | 1311/5209 |
| 近半年 | -13.63% | 3864/4920 |
| 近一年 | 7.83% | 1258/4366 |
| 近两年 | 36.66% | 2026/2954 |
| 近三年 | 20.24% | 1450/2253 |
| 成立以来 | 80.40% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
8.44% 115/4961 |
-6.45% 3698/5312 |
- - |
- - |
| 2025 | 12.91% 2673/4813 |
-2.42% 2885/3635 |
0.92% 2530/4076 |
8.81% 3395/4524 |
5.37% 450/4813 |
| 2024 | 13.64% 1120/3463 |
6.83% 277/2808 |
0.54% 584/3014 |
9.16% 2712/3129 |
-3.07% 2249/3463 |
| 2023 | -2.28% 572/2656 |
11.97% 321/2280 |
0.35% 325/2385 |
-6.20% 1454/2515 |
-7.28% 2106/2655 |
| 2022 | -14.75% 390/2207 |
-8.46% 283/1919 |
4.18% 1045/2016 |
-12.18% 663/2113 |
1.79% 1137/2208 |
| 2021 | 13.87% 349/1822 |
4.60% 142/1255 |
4.57% 870/1330 |
5.34% 277/1466 |
-1.17% 1323/1822 |
| 2020 | - - |
- - |
-0.41% 1019/1067 |
16.24% 159/1164 |
10.90% 576/1184 |
| 2019 | - - |
- - |
- - |
- - |
- - |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 天弘恒生沪深港创新药精选50ETF | 0.8428 | 28.18% |
| 港股通药 | 0.8930 | 27.53% |
| 天弘恒生沪深港创新药精选50ETF发起联接A | 1.2971 | 26.78% |
| 华富中证港股通创新药指数型发起式C | 1.1445 | 26.30% |
| 万家中证港股通创新药ETF | 1.5973 | 26.27% |
| 景顺长城中证港股通创新药ETF | 1.6587 | 26.20% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2831 | 25.87% |
| 港医疗 | 0.8885 | 25.59% |
| 景顺长城中证港股通创新药ETF联接A | 1.4594 | 25.50% |
| 华富中证港股通创新药指数型发起式A | 1.1526 | 25.42% |
| 汇添富中证国企一带一路ETF联接C VS. 长安沪深300非周期A(740101) |